Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To delineate the effect of MSM on osteoarthritis
Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MSM group | Experimental | Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total) |
|
| Placebo Group | Placebo Comparator | Placebo 3 gr twice a day for 26 weeks (6 gr/day total) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MethylSulfonylMethane (MSM) | Drug | Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with improved Mobility | Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC) | 26 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Scores on the Visual Analog Scale | On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life) | 26 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Thomas Pagonis, MD, PhD | Contact | 00306980488686 | iatros1@yahoo.com |
| Name | Affiliation | Role |
|---|---|---|
| Thomas Pagonis, MD, PhD | Aristotle's University of Thessaloniki | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| G. Papanikolaou Hospital | Recruiting | Thessaloniki | Thessaloniki | 57010 | Greece |
Not provided
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C025910 | dimethyl sulfone |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug |
|